QT Imaging Strengthens Strategy with USC Expert
QT Imaging Holdings announced that Mary W. Yamashita, MD, will serve as medical advisor to the company. Yamashita, who serves as Section Chief of Breast Imaging at the University of Southern California Keck School of Medicine and Medical Director of Mammography at two USC breast centers, brings decades of clinical and academic expertise in breast cancer screening and diagnosis.
Strategic Role in Platform Development
In her new role, Dr. Yamashita will provide strategic advisory and development support across clinical interpretation standards, structured reporting frameworks, training architecture, and reader study design. Her expertise will be instrumental in optimizing clinical integration and user experience for QT Imaging’s 3D breast ultrasound technology, which recently obtained a dedicated CPT code.
“Through her research, publications, clinical practice, and lectures, Dr. Yamashita has been a strong advocate for advanced imaging in women with dense breast tissue,” said Raluca Dinu, PhD, CEO of QT Imaging. “Her appointment underscores our commitment to clinical excellence and evidence-based deployment.”
Distinguished Academic and Clinical Career
Dr. Yamashita received her medical degree from the USC Keck School of Medicine and completed diagnostic radiology residency at the University of California, Irvine Medical Center. She pursued fellowship-level training in breast imaging during her final residency year and went on to serve as Medical Director at the Marcia Ray Breast Center and the Patricia L. Scheifly Breast Health Center — one of the busiest breast centers in Southern California.
Since 2006, she has been on faculty at the USC Department of Radiology, maintaining active clinical practice alongside education and mentorship of residents and fellows.
Impact on the Breast Imaging Market
Dr. Yamashita’s appointment comes at a strategic moment for QT Imaging, as the company seeks to expand adoption of its radiation-free 3D breast imaging solution. The breast screening market is transforming, with new AI technologies like Clairity for mammography-based risk prediction and Lancet projections on rising cases through 2050 driving demand for complementary modalities.
“As a breast radiologist, I understand the critical importance of early detection and the ongoing need for improved imaging modalities,” said Dr. Yamashita. QT Imaging’s technology, offering radiation-free 3D imaging, represents a promising alternative for populations requiring frequent screening.
Source: ITN Online